Decentralized Biosensor Doctrine.
1. Meaning
The Decentralized Biosensor Doctrine is a proposed legal and governance framework for regulating biosensors that collect, analyse, store, or transmit biological information outside conventional centralised laboratories or healthcare institutions.
It is important to clarify that there is no universally recognised, standalone legal doctrine formally called the “Decentralized Biosensor Doctrine.” Rather, it is an analytical framework derived from existing principles of medical-device regulation, privacy, informed consent, product liability, professional negligence, cybersecurity, and constitutional rights.
A biosensor is a device that detects a biological or biochemical substance and converts that detection into a measurable signal. Examples include wearable glucose monitors, portable infectious-disease tests, sweat-analysis sensors, and certain devices that continuously measure physiological indicators.
Roche LumiraDx System | Medizintechnik Patz GmbH
11
The decentralised model allows biological measurements to be collected and processed at locations such as homes, workplaces, rural clinics, mobile medical units, and community health centres rather than exclusively in central laboratories. It can improve healthcare access, but it also creates difficult questions about who is responsible when a sensor malfunctions, sensitive data are disclosed, or an automated result leads to harm.
2. Core principles of the doctrine
The proposed doctrine can be understood through seven principles.
1. Distributed accountability: Responsibility must be allocated among manufacturers, software developers, healthcare providers, data controllers, distributors, and operators according to their respective roles.
2. Scientific reliability: Biosensor readings must be supported by appropriate validation, calibration, accuracy testing, and monitoring for errors.
3. Informed consent: People should understand what biological information is collected, why it is collected, who can access it, and how it may affect them.
4. Privacy and data minimisation: Collection and sharing should be limited to what is reasonably necessary for the stated purpose, subject to applicable law.
5. Safety and proportionality: The greater the potential harm from an incorrect reading, the stronger the required safeguards should be.
6. Traceability and transparency: Systems should preserve appropriate records of sensor readings, software updates, calibration, data transfers, and consequential decisions.
7. Effective remedies: Individuals harmed by defective devices, negligent interpretation, unlawful data use, or discriminatory decisions should have access to appropriate complaint and compensation mechanisms.
These principles are a proposed synthesis of existing legal rules, not a claim that every jurisdiction has enacted a single doctrine containing all seven.
3. Legal framework in India
India does not have a single statute exclusively governing decentralised biosensors. Their legal treatment depends on the device's intended use, the data collected, the parties involved, and the consequences of its use.
A. Medical Devices Rules, 2017
The principal regulatory framework is the Medical Devices Rules, 2017, under the Drugs and Cosmetics Act, 1940. The Central Drugs Standard Control Organisation (CDSCO) administers relevant regulatory functions. Medical devices are classified according to risk, from Class A (low risk) to Class D (high risk).
CDSCO+1
Key legal questions include:
Whether a biosensor is a regulated medical device or in-vitro diagnostic device.
Whether the manufacturer requires an applicable manufacturing or import licence.
Whether clinical investigation or performance evaluation is required.
Whether quality-management, labelling, and post-market safety requirements have been satisfied.
Whether adverse events must be reported and corrective action taken.
A biosensor used only for general wellness may be treated differently from one intended to diagnose an infection, guide insulin dosing, or detect a potentially life-threatening condition. The manufacturer's intended purpose and the applicable regulatory classification are central.
B. Constitutional privacy and autonomy
Article 21 of the Constitution of India protects life and personal liberty, and constitutional privacy principles are relevant when government bodies or other legally accountable actors collect or use sensitive biological information.
The right to privacy can be particularly important where biosensors monitor people continuously, collect intimate physiological signals, or transmit measurements to employers, insurers, public authorities, or third-party platforms.
C. Data-protection law
The Digital Personal Data Protection Act, 2023, is relevant to digital processing of personal data within its scope. Its provisions must be read alongside applicable commencement notifications, rules, exemptions, and other relevant laws. As of 5 November 2026, the Act's principal data-processing provisions have not yet reached their scheduled commencement date, so they should not automatically be treated as fully operational.
lawgratis.com+1
Depending on the circumstances, existing information-technology law, contractual duties, confidentiality obligations, and constitutional protections may also be relevant.
D. Consumer protection and product liability
The Consumer Protection Act, 2019, may provide remedies where a defective biosensor, deficient service, misleading claim, or other legally actionable conduct causes harm. Whether a particular claimant or transaction falls within the statute depends on the facts.
Product liability may involve a defective product, a manufacturing or design defect, inadequate warnings, or negligent provision of services. A decentralised system does not automatically eliminate the responsibility of its manufacturer or service provider.
4. Important case laws and their application
The following cases provide useful legal foundations for analysing decentralised biosensors. These are analogous authorities, not claims that the courts directly established a named Decentralized Biosensor Doctrine.
Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1
Court: Supreme Court of India · Judgment: 24 August 2017
Facts and issue: A nine-judge Constitution Bench considered whether privacy is protected as a fundamental right under the Indian Constitution.
Judgment: The Court unanimously recognised privacy as a fundamental right protected under Article 21 and other freedoms in Part III. The judgment discusses legality, legitimate state purpose, and proportionality in assessing certain invasions of privacy.
nhrc.nic.in+1
Application to decentralised biosensors:
Suppose a public authority distributes wearable biosensors to monitor citizens' health and subsequently uses the readings to track their movements or identify individuals for unrelated enforcement purposes.
The constitutional questions may include:
Is the collection or use authorised by law?
Is the purpose legitimate?
Is the interference proportionate to that purpose?
Are safeguards against misuse adequate?
Legal principle: Biological monitoring cannot be justified merely because technology makes it possible. The legality of the collection and use must be assessed in its actual context.
Case 2: Jacob Mathew v. State of Punjab, (2005) 6 SCC 1
Court: Supreme Court of India · Judgment: 5 August 2005
Facts and issue: The case concerned allegations of medical negligence and the standards applicable to criminal liability for negligent medical treatment.
Judgment: The Supreme Court explained the distinction between civil and criminal medical negligence and discussed the need for a sufficiently high degree of negligence before criminal liability attaches to a medical professional.
Application to decentralised biosensors:
Consider a doctor who receives a warning from a remote biosensor but ignores it without reasonable clinical justification. Alternatively, a doctor might rely on an apparently normal reading despite obvious symptoms requiring further examination.
The relevant questions would include whether the doctor owed a duty of care, whether the conduct fell below the applicable standard, and whether that failure caused the injury. Criminal liability requires the additional elements applicable to the relevant offence.
Legal principle: The availability of digital monitoring does not automatically make a healthcare professional liable for every adverse outcome. Liability depends on the applicable standard of care and the evidence.
The case does not establish that every clinician must act on every sensor alert; clinical context and the device's intended role matter.
Case 3: Spring Meadows Hospital v. Harjol Ahluwalia, (1998) 4 SCC 39
Court: Supreme Court of India · Judgment: 25 March 1998
Facts and issue: The case involved serious injury to a child following medical treatment and the liability of a hospital and medical personnel.
Judgment: The Supreme Court upheld the relevance of consumer-protection remedies in medical-service disputes and addressed the rights of the child patient and the parents who obtained the treatment.
Application to decentralised biosensors:
Suppose a hospital incorporates remote biosensor readings into its patient-monitoring service. A failure to respond appropriately to a clinically significant reading might raise questions about deficient service, depending on the circumstances.
The case helps frame the responsibility of healthcare institutions where technology forms part of a wider service. It does not establish automatic hospital liability whenever a sensor malfunctions.
Legal principle: Digital health technology may be part of a regulated service relationship, and the legal analysis must examine the conduct of the institution and the professionals involved.
Case 4: Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1
Court: Supreme Court of India · Judgment: 16 January 2008
Facts and issue: The case concerned the scope of consent required before medical treatment and surgery.
Judgment: The Supreme Court discussed the requirements of valid consent, including voluntariness, adequate information, and the need for consent to cover the treatment undertaken, subject to recognised exceptions.
Application to decentralised biosensors:
A person may agree to use a glucose monitor for personal healthcare without agreeing to the use of the same readings for employment screening, insurance profiling, or unrelated research.
The consent required for a medical intervention and the lawful basis required for data processing are distinct legal questions. Consent to treatment should not be assumed to authorise every subsequent use of sensor-generated data.
Legal principle: Consent must be evaluated in relation to the particular intervention or use at issue, rather than treated as unlimited permission.
Case 5: Donoghue v. Stevenson, [1932] AC 562
Court: House of Lords, United Kingdom · Judgment: 26 May 1932
Facts and issue: A consumer alleged injury after consuming ginger beer from a sealed bottle containing a decomposed snail.
Judgment: The House of Lords recognised a manufacturer's duty of care towards the ultimate consumer in the circumstances described by the judgment.
Donoghue v. Stevenson Case Report
Application to decentralised biosensors:
A manufacturer that supplies a sensor with a latent defect, inadequate safety instructions, or a foreseeable risk of dangerous measurement errors may face a negligence claim where the applicable law's requirements are satisfied.
For example, an unreliable sensor marketed for monitoring a serious medical condition could expose users to foreseeable harm if its limitations are not adequately addressed.
Legal principle: A manufacturer may owe duties to end users even without a direct contract with each user. The precise duty and available remedy depend on the jurisdiction and facts.
Case 6: Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)
Court: Supreme Court of the United States · Judgment: 28 June 1993
Facts and issue: The Court considered the admissibility of expert scientific testimony in litigation alleging that a drug caused birth defects.
Judgment: The Court held that federal judges must assess whether scientific expert testimony is both relevant and reliably grounded. Relevant considerations include testability, peer review, error rates, standards, and acceptance in the scientific community.
LII / Legal Information Institute+1
Application to decentralised biosensors:
If a party relies on sensor readings to prove that an individual had a particular biological condition, the court may need to examine:
The sensor's validation and known error rate.
Calibration records and maintenance history.
The integrity of the raw data and its transmission.
The software version and analytical method used.
Whether the expert's interpretation is scientifically justified.
Legal principle: A device-generated result should not automatically be treated as conclusive scientific proof. The admissibility and weight of evidence depend on the applicable evidentiary rules.
Jurisdictional qualification: Daubert governs the relevant US federal evidentiary context. It does not directly govern Indian courts, which apply Indian evidence law.
5. Allocation of liability in decentralised biosensor systems
The central challenge is that a decentralised biosensor system usually involves several independent actors. A legal framework must distinguish their responsibilities rather than automatically assigning all liability to one party.
| Actor | Potential legal responsibility |
|---|---|
| Manufacturer | Design defects, manufacturing defects, inadequate warnings, and applicable regulatory non-compliance |
| Software developer | Negligent coding, unsafe updates, or other actionable software defects |
| Healthcare provider | Negligent interpretation, inadequate follow-up, or failure to meet the applicable standard of care |
| Data controller or fiduciary | Unlawful processing, inadequate security, or failure to meet applicable data-protection duties |
| Distributor or importer | Duties imposed by applicable device regulations, product-liability rules, and contractual arrangements |
| Employer or insurer | Unlawful collection, discriminatory use, or other actionable misuse of biological information |
| Testing laboratory | Deficient testing, unreliable validation, or negligent reporting, depending on its role |
These responsibilities may overlap. Contractual terms can help allocate risk between organisations, but they do not necessarily remove statutory duties or rights held by injured individuals.
6. Illustrative legal scenario
Consider a decentralised glucose-monitoring system that sends readings from a wearable sensor to a patient's smartphone and then to a remote clinician.
Wearable biosensor
Measures a biological indicator
Phone and software platform
Processes and transmits readings
Remote healthcare provider
Interprets readings and makes clinical decisions
Potential legal failure points
Incorrect readings caused by a defective sensor.
Data altered or lost during transmission.
An unsafe software update affecting measurement accuracy.
A clinically significant warning ignored without reasonable justification.
Disclosure of readings to an unauthorised third party.
If the patient suffers harm, the investigation should identify the actual failure, determine which party had control over it, establish causation, and apply the relevant statutory or common-law rules.
For example, a manufacturer may be responsible for a proven design defect, while a healthcare provider may separately be responsible for negligent treatment. If the harm results from several contributing failures, more than one party may bear responsibility.
7. Evidentiary requirements
Biosensor disputes often require technical evidence in addition to ordinary documentary evidence.
Important records include:
Device identification, serial number, and regulatory status.
Calibration, maintenance, and validation records.
Raw readings and timestamps.
Software versions, update histories, and audit logs.
Records of alerts, acknowledgements, and clinical responses.
Relevant consent records and data-access logs.
Expert reports addressing accuracy, causation, and foreseeable risks.
A reading may be scientifically useful without being conclusive evidence. The court must distinguish the reliability of the underlying measurement from the reliability of the interpretation drawn from it.
In India, the applicable evidentiary framework, including the Bharatiya Sakshya Adhiniyam, 2023 where applicable, must be considered when digital records are tendered in court. The US Daubert standard should not be substituted for Indian evidentiary rules.
8. Principal legal challenges
First, fragmented accountability. Manufacturers, app operators, clinicians, and data processors may be located in different jurisdictions, making investigation and enforcement difficult.
Second, measurement uncertainty. A sensor can generate false positives, false negatives, or misleading readings due to calibration errors, interference, user behaviour, or software limitations.
Third, privacy risks. Continuous monitoring can reveal sensitive information about a person's health and daily activities, creating risks of unauthorised access or secondary use.
Fourth, unequal access. If essential healthcare decisions depend on costly sensors, reliable internet access, or proprietary platforms, decentralisation may disadvantage people with limited resources.
Fifth, automated decision-making. Organisations may use sensor data to make decisions about employment, insurance, eligibility for services, or healthcare without adequate explanation or review.
A sound regulatory approach should address these risks through proportionate safeguards, clear allocation of duties, independent oversight, and accessible remedies.
9. Proposed legal test for applying the doctrine
A court, regulator, or compliance officer could use the following analytical sequence. This is a proposed framework, not an established judicial test.
Classification: What is the sensor's intended purpose, and which regulatory requirements apply?
Duty: Which actor owed the relevant statutory, contractual, professional, or common-law duty?
Reliability: Was the device sufficiently validated, calibrated, maintained, and used appropriately?
Consent and lawful processing: Was the collection and subsequent use of biological data lawful?
Causation: Did the alleged defect, negligent act, or unlawful disclosure cause the claimed harm?
Responsibility: Which actors contributed to the harm, and what defences or limitations apply?
Remedy: Is the appropriate response regulatory correction, compensation, an injunction, disciplinary action, or another legally available remedy?
10. Conclusion
The Decentralized Biosensor Doctrine is best understood as a proposed framework for applying established legal principles to distributed biological monitoring systems. Its principal concern is ensuring that technological decentralisation does not produce legal unaccountability.
The most useful judicial foundations are Puttaswamy for constitutional privacy, Jacob Mathew for medical negligence, Spring Meadows Hospital for healthcare-service liability, Samira Kohli for informed consent, Donoghue v. Stevenson for manufacturer negligence, and Daubert for scientific evidence in the relevant US federal courts.
None of these decisions, individually or collectively, formally establishes a named Decentralized Biosensor Doctrine. Their relevance lies in the existing principles they contribute to the analysis. In an Indian dispute, the final outcome would depend on the applicable legislation, regulatory classification, evidence, and specific facts.
For academic or legal research, the strongest approach is to treat this doctrine as a structured synthesis of medical-device regulation, constitutional privacy, consent, product liability, professional negligence, and evidentiary reliability—not as a separately enacted rule of law.
RELATED Blog
comments